Articles Mentioning Biotechnology Stocks

Results 1 - 10 of 376 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology

Investing | January 31, 2015

Can You Guess What Legal Drug Outsells the NFL?

The NFL is unquestionably one of the most successful American businesses of all-time. Surprisingly, though, the NFL's 2013 revenues were no match for this single legal drug.

Investing | January 31, 2015

3 Biotech Giants That Shouldn't Pay a Dividend

Three Motley Fool contributors explain why they don't want these large-cap biotech companies to pay a dividend.

Investing | January 24, 2015

These 3 Dividend Stocks Could Crush the Market in 2015

AbbVie, Amgen, and Pfizer are three dividend stocks that could crush the broader market this year. Here's why.

Investing | January 20, 2015

Can AbbVie Inc. Overcome Humira’s Looming Patent Expiration?

AbbVie's most important product, Humira, will lose patent exclusivity in the U.S. in 2016. Should investors fear this upcoming event?

Investing | January 16, 2015

These 3 Stocks Are the Best Buys in Biotech

Gilead Sciences, Amgen, and Biogen Idec could be the best biotech stocks to buy.

Investing | January 14, 2015

3 Stocks to Buy When the Market Crashes

Celgene Corporation, Amgen Inc., and Gilead Sciences may all offer long term opportunity if markets falter.

Investing | January 11, 2015

Should AbbVie Inc. Or Gilead Sciences Buy These Tiny Biotech Stocks?

AbbVie Inc and Gilead Sciences may want to consider Achillion Pharmaceuticals' and Regulus Therapeutics' intriguing hepatitis C drugs.

Investing | January 11, 2015

5 Predictions for Biotechnology Stocks in 2015

Celgene Corp, Alkermes, GW Pharmaceuticals, Gilead Sciences, and Hospira should all be on investors radar in 2015.

Investing | January 11, 2015

The Surprising Thing Most of 2014's Top 10 Stocks Have in Common

8 out of 10 of last year's best-performing stocks have this one important common denominator.

Investing | January 09, 2015

Is Gilead Sciences Inc. Now a Takeover Target?

Gilead Sciences looks cheap based on its present valuation metrics and growth prospects going forward. Will a growth-starved big pharma decide to pursue a merger with this high flying biotech in 2015?

Results 1 - 10 of 376 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology